EWTX Q4 2024 Earnings — Edgewise Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

EWTXEdgewise Therapeutics, Inc.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$46M

Net Income

-$40M

EPS (Diluted)

$-0.42

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$487M

Total Liabilities

$28M

Stockholders' Equity

$459M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$46M	-$34M	-34.5%
Net Income	-$40M	-$30M	-31.6%